Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market

This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.

Detalles Bibliográficos
Autores principales: Dean, Emma Boswell, Bond, Amelia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796923/
https://www.ncbi.nlm.nih.gov/pubmed/35977178
http://dx.doi.org/10.1001/jamahealthforum.2021.2634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796923/
https://www.ncbi.nlm.nih.gov/pubmed/35977178
http://dx.doi.org/10.1001/jamahealthforum.2021.2634

Ejemplares similares